A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

IRB/UVA Tracking #
21913
Contact
Gracie Hockenberry
Contact Email
Contact Phone
1.434.297.7784
Phase
II
Primary purpose
Treatment
Cancer PI
Richard Hall
Status
OPEN TO ACCRUAL
Ages
Adult